Close

Leerink Swann Upgrades Myriad Genetics (MYGN) to Outperform; Growth Prospects Good, Risks Overdone

Go back to Leerink Swann Upgrades Myriad Genetics (MYGN) to Outperform; Growth Prospects Good, Risks Overdone